Publications

5543 Results

Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226

Authors
D Rutherford;S Medley;N Henderson;C Gersch;T Vandenberg;K Albain;S Dakhil;N Tirumali;J Gralow;G Hortobagyi;L Pusztai;R Mehta;D Hayes;K Kidwell;NL Henry;W Barlow;J Rae;D Hertz
Journal / Conference
Pharmacogenomics Aug;24(12):665-673
Year
2023
Research Committee(s)
Breast
PMID
PMID37615099
PMC
PMC10565537
Study Number(s)
S0226

Combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607

Authors
S Hu-Lieskovan;J Moon;J Hyngstrom;K Campbell;G In;T Logan;K Kendra;D Wang;D Johnson;G Doolittle;A Tan;Ann Silk;K Grossmann;C Ryan;SP Patel;S Bellasea;M Wu;J Kirkwood;H Chen;A Ribas
Journal / Conference
AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster; Cancer Research Volume 83, Issue 7_Supplement 1 April 2023
Year
2023
Research Committee(s)
Melanoma
Study Number(s)
S1607

Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP)

Authors
R Vaidya;J Unger;L Qian;K Minichiello;R Herbst;D Gandara;J Neal;T Leal;J Patel;K Dragnev;S Waqar;M Edelman;E Sigal;S Adam;S Malik;C Blanke;M LeBlanc;K Kelly;J Gray;M Redman
Journal / Conference
JCO Precision Oncology Sep;7:e2300218
Year
2023
Research Committee(s)
Lung
PMID
PMID37677122
PMC
PMC10581630
Study Number(s)
LUNGMAP

An analysis of the rate of second primary lung cancer from CALGB/Alliance 140503 trial of lobar versus sub-lobar resection for T1aN0 NSCLC

Authors
T Stinchcombe;X Wang;B Damman;J Mentlick;R Landreneau;D Wigle;D Jones;M Conti;A Ashrafi;M Liberman;M DePerrot;J Mitchell;R Keenan;T Bauer;D Miller;N Altorki
Journal / Conference
WCLC (September 9 to 12, 2023, Singapore), oral presentation #OA12.03
Year
2023
Research Committee(s)
Lung

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

Authors
C Ryan;A Saif;F Rocha;P Philip;J Hernandez;S Ahmad;H Soares
Journal / Conference
Ann Surg Oncol. Mar;30(3):1302-1304
Year
2023
Research Committee(s)
Gastrointestinal
PMID
PMID36474095
Study Number(s)
S2104

Adjusted Indirect Treatment Comparison of Progression-Free Survival Associated With D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

Authors
B Durie;S Kumar;E Ammann;A Fu;S Kaila;A Lam;S Usmani;T Facon
Journal / Conference
Proceedings Society of Hematologic Oncology 2023 Annual Meeting; Lymphoma, Myeloma & Leukemia Vol 23 Suppl 1S1-S593, poster
Year
2023
Research Committee(s)
Myeloma
Study Number(s)
S0777

A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts

Authors
Y Chae;M Othus;S Patel;F Backes;D O'Malley;M Cristea;A Naing;K Kurnit;R Eskander;S Goodrich;L Il-Young Chung;C McLeod;H Chen;E Sharon;H Streicher;C Ryan;CD Blanke;R Kurzrock
Journal / Conference
AACR Annual Meeting (April 14-19, 2023, Orlando, FL, poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers
Study Number(s)
S1609

S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma

Authors
K Kendra;S Bellasea;Z Eroglu;S Hu-Lieskovan;K Campbell;W Carson;D Wada;J Plaza;J Sosman;G In;A Ikeguchi;J Hyngstrom;A Brohl;N Khushalani;J Markowitz;G Negrea;S Kasbari;G Doolittle;U Swami;T Roberts;S Patel;E Sharon;J Moon;M Wu;A Ribas
Journal / Conference
AACR Annual Meeting (April 14-19, 2023, Orlando, FL, oral
Year
2023
Research Committee(s)
Melanoma
Study Number(s)
S1512

Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation

Authors
R Vaidya;J Unger;N Schwartz;R Loomba;J Hwang;R Chugh;M Tincopa;K Arnold;D Hershman;S Ramsey
Journal / Conference
Cancer Research Communications Sep 28 3(9):1959-1965. doi:10.1158/2767-9764.CRC-23-0255
Year
2023
Research Committee(s)
Cancer Care Delivery
PMID
PMID37707388
PMC
PMC10541082
Study Number(s)
S1204

A Phase III Randomized Trial of Eribulin (E) with or without gemcitabine vs Standard of Care (SOC) for Metastatic Urothelial Carcinoma (UC) Refractory to or ineligible for PD/PDL1 Antibody (Ab): SWOG S1937 (ClicalTrials.gov NCT04579224)

Authors
S Sadeghi;M Plets;P Lara;C Tangen;R Bangs;S Lerner;T Flaig;D Petrylak;I Thompson
Journal / Conference
J Clin Oncol 41, 2023 (suppl 6; abstr TPS581); ASCO GU Cancers Symposium (Feb 16-18, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1937